Trial
NCT02134015
Study of Patritumab in Combination With Erlotinib in Subjects With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC). (HER3-Lung)
Phase IIITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Daiichi Sankyo
Collaborators
Parexel
Condition
Lung Cancer
Intervention
Patritumab
Why stopped
Pre-defined criteria for continuation were not reached
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2018-01-23